Bibliografia
- Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Jama 1998; 279 (2): 125–129.
- Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073–1081.
- Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer HB, Pierce PF. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45 (10): 2793–2797.
- Wright DH, Brown GH, Peterson ML, Rotschafer JC. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000; 46 (5): 669–683.
- Geddes A, Thaler M, Schonwald S, Harkonen M, Jacobs F, Nowotny I. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 1999; 44 (6): 799–810.
- Peacock JE, Herrington DA, Wade JC, et al. Ciprofloxacin plus piperacillin compared with tobramycin plus piperacillin as empirical therapy in febrile neutropenic patients. A randomized, double-blind trial. Ann Intern Med 2002; 137 (2): 77–87.
- Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163 (7): 1730–1754.
- American Thoracic Society. Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies. A consensus statement, American Thoracic Society, November 1995. Am J Respir Crit Care Med 1996; 153 (5): 1711–1725.
- Barcenilla F, Gasco E, Rello J, Alvarez-Rocha L. Antibacterial treatment of invasive mechanical ventilation-associated pneumonia. Drugs Aging 2001; 18 (3): 189–200.
- Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of levofloxacin 500 mg bid IV in ICU patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42 (6): 589–598.
- Langtry HD,Lamb HM. Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. Drugs 1998; 56 (3): 487–515.
- Furlanut M, Brollo L, Lugatti E, et al. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. J Antimicrob Chemother 2003; 51 (1): 101–106.
- Naber CK, Hammer M, Kinzig-Schippers M, Sorgel F, Naber KG. Urinary excretion and bactericidal activities of levofloxacin versus ciprofloxacin in healthy volunteers after a single oral dose of 500 mg. Abstract at the 9th Int Congress of Infectious Diseases, Buenos Aires Argentina 2000; Poster 10920.
- Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17 (4): 331–341.
- Pea F, Pavan F, Di Qual E, et al. Profilo delle concentrazioni urinarie di levofloxacina in pazienti ICU trattati con 500 mg bid per polmonite associata a ventilazione meccanica (VAP). Abstract al VI Convegno Nazionale IBAT, Napoli 22–25 gennaio 2003; 242.
- Lipman J, Allworth A, Wallis SC. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 2000; 31 (5): 1131–1133.
- Scotton PG, Pea F, Giobbia M, Baraldo M, Vaglia A, Furlanut M. Cerebrospinal fluid penetration of levofloxacin in patients with spontaneous acute bacterial meningitis. Clin Infect Dis 2001; 33 (9): e109–111.
- Pea F, Pavan F, Nascimben E, et al. Farmacocinetica di levofloxacina nel liquido cerebrospinale di pazienti con ventricolostomia esterna. Abstract al VI Convegno Nazionale IBAT, Napoli 22–25 gennaio 2003; 241.
- Lutsar I,Friedland IR. Pharmacokinetics and pharmacodynamics of cephalosporins in cerebrospinal fluid. Clin Pharmacokinet 2000; 39 (5): 335–343.